Last reviewed · How we verify

CT-guided corticosteroid+ bupivicaine

Montefiore Medical Center · FDA-approved active Small molecule

A CT-guided injection combining a corticosteroid and local anesthetic to reduce inflammation and provide pain relief at a targeted anatomical site.

A CT-guided injection combining a corticosteroid and local anesthetic to reduce inflammation and provide pain relief at a targeted anatomical site. Used for CT-guided injection for inflammatory lesions or joint pain, Localized pain and inflammation management.

At a glance

Generic nameCT-guided corticosteroid+ bupivicaine
SponsorMontefiore Medical Center
Drug classCorticosteroid + local anesthetic combination injection
ModalitySmall molecule
Therapeutic areaPain Management / Rheumatology / Interventional Medicine
PhaseFDA-approved

Mechanism of action

Corticosteroids suppress inflammatory responses by inhibiting cytokine production and immune cell activation, while bupivacaine is a local anesthetic that blocks nerve conduction. When delivered together via CT guidance to a specific lesion or joint, this combination provides both anti-inflammatory and analgesic effects with high anatomical precision.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: